8 results on '"Cipemastat"'
Search Results
2. Repetitive Aerosol Exposure Promotes Cavitary Tuberculosis and Enables Screening for Targeted Inhibitors of Extensive Lung Destruction.
- Author
-
Urbanowski, Michael E., Ihms, Elizabeth A., Bigelow, Kristina, Kübler, André, Elkington, Paul T., and Bishai, William R.
- Subjects
- *
MYCOBACTERIUM tuberculosis , *LUNG diseases , *MATRIX metalloproteinases , *RABBITS , *BACTERIAL diseases - Abstract
Background. Cavitation is a serious consequence of tuberculosis. We tested the hypothesis that repetitive exposure to the same total bacterial burden of Mycobacterium tuberculosis drives greater lung destruction than a single exposure. We also tested whether inhibition of endogenous matrix metalloproteinase-1 (MMP-1) may inhibit cavitation during tuberculosis. Methods. Over a 3-week interval, we infected rabbits with either 5 aerosols of 500 colony-forming units (CFU) of M. tuberculosis or a single aerosol of 2500 CFU plus 4 sham aerosols. We administered the MMP-1 inhibitor cipemastat (100 mg/kg daily) during weeks 5-10 to a subset of the animals. Results. Repetitive aerosol infection produced greater lung inflammation and more cavities than a single aerosol infection of the same bacterial burden (75% of animals vs 25%). Necropsies confirmed greater lung pathology in repetitively exposed animals. For cipemastat-treated animals, there was no significant difference in cavity counts, cavity volume, or disease severity compared to controls. Conclusions. Our data show that repetitive aerosol exposure with M. tuberculosis drives greater lung damage and cavitation than a single exposure. This suggests that human lung destruction due to tuberculosis may be exacerbated in settings where individuals are repeatedly exposed. MMP-1 inhibition with cipemastat did not prevent the development of cavitation in our model. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis Paradoxically Worsens Pathology
- Author
-
Andre Kubler, Sanjay K. Jain, Michael E. Urbanowski, Mariah H. Klunk, Supriya Pokkali, William R. Bishai, Paul T. Elkington, Alvaro A. Ordonez, and Julian Sanchez-Bautista
- Subjects
0301 basic medicine ,Tuberculosis ,Matrix metalloproteinase inhibitor ,Matrix Metalloproteinase Inhibitors ,Matrix metalloproteinase ,Pathogenesis ,Major Articles and Brief Reports ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Immunopathology ,medicine ,Animals ,Immunology and Allergy ,030212 general & internal medicine ,Tuberculosis, Pulmonary ,Mice, Inbred C3H ,Lung ,business.industry ,Mycobacterium tuberculosis ,Hypoxia (medical) ,medicine.disease ,Survival Analysis ,Disease Models, Animal ,030104 developmental biology ,Infectious Diseases ,medicine.anatomical_structure ,chemistry ,Matrix Metalloproteinase 7 ,Cancer research ,Cipemastat ,Female ,medicine.symptom ,business - Abstract
Matrix metalloproteinases (MMPs) degrade extracellular matrix and are implicated in tuberculosis pathogenesis and cavitation. In particular, MMP-7 is induced by hypoxia and highly expressed around pulmonary cavities of Mycobacterium tuberculosis–infected C3HeB/FeJ mice. In this study, we evaluated whether administration of cipemastat, an orally available potent inhibitor of MMP-7, could reduce pulmonary cavitation in M. tuberculosis–infected C3HeB/FeJ mice. We demonstrate that, compared with untreated controls, cipemastat treatment paradoxically increases the frequency of cavitation (32% vs 7%; P = .029), immunopathology, and mortality. Further studies are needed to understand the role of MMP inhibitors as adjunctive treatments for pulmonary tuberculosis.
- Published
- 2018
4. Matrix Metalloproteinases and Their Inhibitions in Experimental Renal Scarring
- Author
-
Graham L. Thomas, Marie Fisher, Timothy S. Johnson, John L. Haylor, and A. Meguid El Nahas
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Physiology ,Matrix metalloproteinase ,Biology ,Kidney ,Nephropathy ,Extracellular matrix ,chemistry.chemical_compound ,Fibrosis ,Genetics ,medicine ,Renal fibrosis ,Animals ,RNA, Messenger ,Rats, Wistar ,Heparin ,Tissue Inhibitor of Metalloproteinases ,General Medicine ,medicine.disease ,Matrix Metalloproteinases ,Fibronectins ,Rats ,Cell biology ,medicine.anatomical_structure ,chemistry ,Nephrology ,Cipemastat ,Collagenase ,Proteoglycans ,Collagen ,Laminin ,medicine.drug - Abstract
Renal fibrosis is characterised by an excessive accumulation of extracellular matrix (ECM) proteins. Evidence suggests that this results from both increased ECM synthesis and a reduced degradation. Here, we determine changes in the matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) in relation to ECM production and the progression of renal fibrosis in subtotally nephrectomized (SNx) rats. Groups of 4–6 SNx or sham-operated male Wistar rats were sacrificed between days 7 and 120 following surgery. Total RNA was analysed by Northern blotting. Messenger RNA for collagens I (+710%), III (+674%), and IV (+358%) were significantly (p < 0.05) raised by day 7 and remained elevated over the 120 days. Significant (p < 0.05) increase in fibronectin, laminin and heparan sulfate proteoglycan mRNAs occurred latter at days 60 (+224%), 120 (+210%), and 120 (+256%), respectively. Increases (p < 0.05) in mRNA for MMP-1 (+360%) and MMP-2 (+239%) occurred from day 7 with MMP-1 reaching +881% by day 120. MMP-3 and -9 showed no change. Zymography on day 90 remnant kidneys showed mRNA changes were translated into active MMP-1 (+1,700%) and MMP-2 (+440%), p < 0.05. TIMP-1 mRNA was also raised (+548%, p < 0.05) by day 7 and remained elevated, while TIMP-2 mRNA levels only reached significance by day 120 (+165%). In contrast, TIMP-3 mRNA was decreased by day 30 (p > 0.05) and dropped to 27% of control by day 120. However, Western blot analysis of TIMPs 1 and 3 at day 90 showed a 5- and 4-fold increase respectively, while TIMP-2 levels were not significantly altered. Measurements of overall collagenase activities in remnant kidney homogenates were reduced. Using collagen I and IV substrates, proteolytic activity in remnant kidneys dropped to 40 and 27% of controls (p < 0.01), respectively. This data suggests that reduced MMP activity may contribute towards renal scarring, however this is not a result of reduced MMP transcription or activation, but likely to be due to the inhibition by TIMPs.
- Published
- 2002
5. The synthesis of labelled forms of cipemastat
- Author
-
G Maile, K. J. Prior, H. R. Wiltshire, and J. Dhesi
- Subjects
chemistry.chemical_classification ,Hydroxamic acid ,biology ,medicine.drug_class ,Chemistry ,Stereochemistry ,Organic Chemistry ,Carboxamide ,Biochemistry ,Chemical synthesis ,Analytical Chemistry ,chemistry.chemical_compound ,Enzyme ,Enzyme inhibitor ,Amide ,Drug Discovery ,medicine ,Cipemastat ,biology.protein ,Radiology, Nuclear Medicine and imaging ,Glucuronide ,Spectroscopy - Abstract
The development of the collagenase inhibitor, cipemastat (Ro 32-3555), required the synthesis of both carbon-14 labelled and deuteriated material for the measurement of the parent drug and drug-related material in biological fluids. In addition, labelled metabolites were needed for both in vitro metabolism and analytical studies. This paper describes the synthesis of labelled forms of cipemastat and its amide (Ro 32-4778) and glucuronide (Ro 32-6414) metabolites. Copyright © 2001 John Wiley & Sons, Ltd.
- Published
- 2001
6. Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis Paradoxically Worsens Pathology.
- Author
-
Ordonez, Alvaro A, Pokkali, Supriya, Sanchez-Bautista, Julian, Klunk, Mariah H, Urbanowski, Michael E, Kübler, André, Bishai, William R, Elkington, Paul T, Jain, Sanjay K, and Kübler, André
- Subjects
- *
TUBERCULOSIS mortality , *ANIMALS , *BIOLOGICAL models , *MICE , *MYCOBACTERIUM tuberculosis , *PROTEOLYTIC enzymes , *SURVIVAL analysis (Biometry) , *TUBERCULOSIS , *PROTEASE inhibitors - Abstract
Matrix metalloproteinases (MMPs) degrade extracellular matrix and are implicated in tuberculosis pathogenesis and cavitation. In particular, MMP-7 is induced by hypoxia and highly expressed around pulmonary cavities of Mycobacterium tuberculosis-infected C3HeB/FeJ mice. In this study, we evaluated whether administration of cipemastat, an orally available potent inhibitor of MMP-7, could reduce pulmonary cavitation in M. tuberculosis-infected C3HeB/FeJ mice. We demonstrate that, compared with untreated controls, cipemastat treatment paradoxically increases the frequency of cavitation (32% vs 7%; P = .029), immunopathology, and mortality. Further studies are needed to understand the role of MMP inhibitors as adjunctive treatments for pulmonary tuberculosis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. A selective inhibitor of matrix metalloproteinases inhibits the migration of isolated osteoclasts by increasing the life span of podosomes
- Author
-
Teruo Tanaka, Hidefumi Maeda, and Tetsuya Goto
- Subjects
musculoskeletal diseases ,Podosome ,Matrix metalloproteinase inhibitor ,Endocrinology, Diabetes and Metabolism ,Glycine ,Osteoclasts ,Matrix metalloproteinase ,Biology ,Cysteine Proteinase Inhibitors ,Matrix Metalloproteinase Inhibitors ,Hydroxamic Acids ,Bone resorption ,chemistry.chemical_compound ,Endocrinology ,Osteoclast ,Cell Movement ,Leucine ,medicine ,Animals ,Orthopedics and Sports Medicine ,Protease Inhibitors ,Bone Resorption ,Cells, Cultured ,Molecular Structure ,General Medicine ,Actins ,Matrix Metalloproteinases ,Cell biology ,Resorption ,medicine.anatomical_structure ,chemistry ,Immunology ,Cipemastat ,Cinemicrography ,Rabbits - Abstract
The osteoclast is a unique cell that cycles between bone resorption and migration. In this study, we used KB-R7785, an inhibitor of matrix metalloproteinases (MMPs), to investigate the role of MMPs in this cycle. Osteoclasts prepared from neonatal rabbits were processed to measure: (1) migration on hydroxyapatite (HA)-coated dishes, (2) the formation of an actin band, which is a large collection of podosomes, (3) the life span of podosomes, and (4) lacunar resorption on ivory slices. KB-R7785 significantly decreased the area of the tracks formed by osteoclasts on HA-coated dishes. The percentage of actin/podosome band formation, expressed as: (total length of the actin band/circumference of the osteoclast) × 100, was significantly increased after the addition of KB-R7785, which implies that podosome disassembly in osteoclasts was decreased by the inhibition of MMPs. Time-lapse cinemicrography demonstrated that the addition of KB-R7785 increased the life span of podosomes. Several indexes (number of resorption pits, total resorption area, and mean resorption area) of osteoclast resorption activity were significantly decreased by KB-R7785, while the average depth of resorption was increased. These results indicate that decreased podosome disassembly caused by an MMP inhibitor suppresses the migration of osteoclasts and, ultimately, inhibits osteoclastic bone resorption.
- Published
- 2001
8. Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis
- Author
-
Tim Shaw, John S. Nixon, and Kevin M. K. Bottomley
- Subjects
Drug ,media_common.quotation_subject ,medicine.medical_treatment ,Osteoarthritis ,Matrix metalloproteinase ,Arthritis, Rheumatoid ,chemistry.chemical_compound ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Protease Inhibitors ,media_common ,Pharmacology ,Metalloproteinase ,business.industry ,Tumor Necrosis Factor-alpha ,Metalloendopeptidases ,General Medicine ,medicine.disease ,Cytokine ,chemistry ,Rheumatoid arthritis ,Immunology ,Cipemastat ,business ,Marimastat ,medicine.drug - Abstract
The clinical efficacy of anti-TNF-alpha therapies have highlighted the apparently central role that TNF-alpha plays in the pathology of rheumatoid arthritis, particularly the inflammatory component. Recent identification of a metalloproteinase from the metzincin superfamily responsible for the production of the soluble form of this cytokine, has generated a large amount of pharmaceutical interest and presents the prospect of a metalloproteinase inhibitor as an anti-inflammatory drug. However, the traditional focus of metzincin inhibitor research has been the identification of inhibitors of matrix metalloproteinases; enzymes associated with matrix destruction, a feature common to both rheumatoid arthritis and osteoarthritis. Inhibitors of this class of metalloproteinase are now in clinical evaluation in patients. This review summarises the current development status of metalloproteinase inhibitors in arthritic diseases and discusses some of the issues that have arisen during their progress to become clinical treatments for these diseases.
- Published
- 2000
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.